Ophthalmology treatments and biotech updates from Eyepoint Pharmaceuticals

Eyepoint Pharmaceuticals is advancing potential therapies targeting serious retinal diseases such as diabetic macular edema (DME) as part of its observance of Mens Health Month in June. The ...

Eyepoint Pharmaceuticals announced that members of its management team will participate in a fireside chat at the 2026 Jefferies Global Healthcare Conference in New York tomorrow. The company ...

Eyepoint Pharmaceuticals president and CEO Jay S. Duker, M.D., has been recognized in Retina Today’s ‘Then and Now’ spotlight for his perspective on the progress of optical coherence ...

Eyepoint Pharmaceuticals is intensifying efforts to translate scientific discovery into tangible therapies for patients with severe retinal diseases. The company is spotlighting its Northbridge, ...

Eyepoint Pharmaceuticals released its financial results for the first quarter of 2026, providing insight into recent corporate performance. The company reported progress in its pivotal Phase 3 ...

Eyepoint Pharmaceuticals is pushing forward with its pivotal Phase 3 program aimed at addressing diabetic macular edema (DME), following ongoing challenges with current anti-VEGF therapies that ...

Eyepoint Pharmaceuticals has appointed Michael Campbell as Chief Commercial Officer (CCO). With over 30 years of commercial leadership experience and a proven track record in product launches, ...

Eyepoint Pharmaceuticals has announced a significant milestone for its pivotal Phase 3 wet AMD program. The independent Data Safety Monitoring Committee has issued a positive recommendation for ...

Eyepoint Pharmaceuticals has announced an ambitious pivotal Phase 3 program targeting diabetic macular edema (DME). The company anticipates dosing its first patient in the first quarter of 2026. ...